» Articles » PMID: 31234648

Risk Prediction Tools in Cardiovascular Disease Prevention: A Report from the ESC Prevention of CVD Programme Led by the European Association of Preventive Cardiology (EAPC) in Collaboration with the Acute Cardiovascular Care Association (ACCA) And...

Abstract

Risk assessment have become essential in the prevention of cardiovascular disease. Even though risk prediction tools are recommended in the European guidelines, they are not adequately implemented in clinical practice. Risk prediction tools are meant to estimate prognosis in an unbiased and reliable way and to provide objective information on outcome probabilities. They support informed treatment decisions about the initiation or adjustment of preventive medication. Risk prediction tools facilitate risk communication to the patient and their family, and this may increase commitment and motivation to improve their health. Over the years many risk algorithms have been developed to predict 10-year cardiovascular mortality or lifetime risk in different populations, such as in healthy individuals, patients with established cardiovascular disease and patients with diabetes mellitus. Each risk algorithm has its own limitations, so different algorithms should be used in different patient populations. Risk algorithms are made available for use in clinical practice by means of - usually interactive and online available - tools. To help the clinician to choose the right tool for the right patient, a summary of available tools is provided. When choosing a tool, physicians should consider medical history, geographical region, clinical guidelines and additional risk measures among other things. Currently, the U-prevent.com website is the only risk prediction tool providing prediction algorithms for all patient categories, and its implementation in clinical practice is suggested/advised by the European Association of Preventive Cardiology.

Citing Articles

The European Society of Cardiology 2024 Guidelines on Chronic Coronary Syndromes: A Critical Appraisal.

Ferrari R, Gowdak L, Padilla F, Quek D, Ray S, Rosano G J Clin Med. 2025; 14(4).

PMID: 40004691 PMC: 11856662. DOI: 10.3390/jcm14041161.


Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy.

Cesaro A, Acerbo V, Scialla F, Golia E, Concilio C, Scherillo G High Blood Press Cardiovasc Prev. 2025; 32(2):199-208.

PMID: 39969794 PMC: 11890243. DOI: 10.1007/s40292-025-00705-0.


Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.

Fabiani I, Chianca M, Cipolla C, Cardinale D Nat Rev Cardiol. 2025; .

PMID: 39875555 DOI: 10.1038/s41569-025-01126-1.


Mitochondrial Dysfunction and Risk Factors for Noncommunicable Diseases: From Basic Concepts to Future Prospective.

Nevoit G, Jarusevicius G, Potyazhenko M, Mintser O, Bumblyte I, Vainoras A Diseases. 2024; 12(11).

PMID: 39589951 PMC: 11592525. DOI: 10.3390/diseases12110277.


Recommendations for prediction models in clinical practice guidelines for cardiovascular diseases are over-optimistic: a global survey utilizing a systematic literature search.

Jing C, Zhang L, Feng L, Li J, Liang L, Hu J Front Cardiovasc Med. 2024; 11:1449058.

PMID: 39484015 PMC: 11524858. DOI: 10.3389/fcvm.2024.1449058.